checkAd

NeoGenomics, Inc. Expands Its Global Strategic Partnership Initiatives with Biognosys AG on Multiple Next Generation Proteomics Solutions Supporting Biopharma R&D

NeoGenomics continues to add to its state-of-the-art multiomics solutions in world-class biopharma clinical trial and research services for global pharma companiesFORT MYERS, FL / ACCESSWIRE / April 11, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a …

NeoGenomics continues to add to its state-of-the-art multiomics solutions in world-class biopharma clinical trial and research services for global pharma companies

FORT MYERS, FL / ACCESSWIRE / April 11, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services announced a global strategic partnership agreement with Biognosys AG, a Switzerland-based leader in next-generation proteomics solutions for drug discovery and development this week. This partnership strengthens NeoGenomics' proteomics-based product capabilities for its Pharma Services Division from early discovery translational research through clinical trial work in oncology drug development programs.

"The need of our pharma customers to access the next state-of-the-art technology to improve diagnostics and clinical trials is top priority for us," said Gina Wallar, PhD., President, Pharma Services, NeoGenomics Laboratories, Inc. "Partnering with Biognosys gives us the added advantage of expanding into proteomics, data analytics and subsequent actionable results, not only in early discovery and translational research but ultimately, in clinical trials impacting patient care."

In a collaborative scientific effort, NeoGenomics and Biognosys AG have designed a multi-modality approach for the protein analysis of tumor samples from late-stage melanoma patients treated with immune-checkpoint inhibitors (ICIs), demonstrating the power of a dual proteomic and multiplexed immunofluorescence (mIF) profiling for a comprehensive characterization of melanoma patients along with discovery and detection of markers for predictive response to ICI-therapy. The collaboration combines Biognosys' TrueDiscovery™ unbiased proteomics platform based on proprietary mass spectrometry technology with mIF spatial tissue analysis using MultiOmyx™, a NeoGenomics proprietary platform. This data will be presented with two posters by NeoGenomics and Biognosys at the American Association for Cancer Research (AACR), held this year at New Orleans, LA, April 8-13.

"At Biognosys we continuously push the boundaries of what is possible with our proteomics solutions to address key challenges in drug development. Our platforms are transforming research from early drug discovery to clinical biomarker identification," said Kristina Beeler, PhD., Chief Business Officer, Biognosys. "We are excited to now combine our proteomics platforms with NeoGenomics' immuno-profiling platform to advance our biopharma partners' oncology drug development programs."

Seite 1 von 3


Wertpapier



0 Kommentare
Nachrichtenquelle: Accesswire
 |  178   |   |   

Schreibe Deinen Kommentar

Disclaimer

NeoGenomics, Inc. Expands Its Global Strategic Partnership Initiatives with Biognosys AG on Multiple Next Generation Proteomics Solutions Supporting Biopharma R&D NeoGenomics continues to add to its state-of-the-art multiomics solutions in world-class biopharma clinical trial and research services for global pharma companiesFORT MYERS, FL / ACCESSWIRE / April 11, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a …

Nachrichten des Autors

122 Leser
120 Leser
114 Leser
111 Leser
102 Leser
102 Leser
101 Leser
101 Leser
100 Leser
100 Leser
130 Leser
122 Leser
120 Leser
118 Leser
115 Leser
114 Leser
111 Leser
109 Leser
109 Leser
109 Leser
1234 Leser
821 Leser
461 Leser
378 Leser
332 Leser
315 Leser
308 Leser
244 Leser
243 Leser
229 Leser
4528 Leser
1731 Leser
1234 Leser
1125 Leser
942 Leser
906 Leser
897 Leser
821 Leser
766 Leser
658 Leser